drugset / Trial / NCT00002388

A Study of 1592U89 in HIV-Infected Patients

NCT00002388 ↗

Phase 1 Completed 48 enrolled Glaxo Wellcome
Treatment

Summary

The purpose of this study is to see if it is safe to give 1592U89 to HIV-infected patients. This study also examines the effect 1592U89 has on plasma viral load (the level of HIV in the blood).

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Abacavir Other / unclassified — —